Evidence map›Paper›PMID 42882845›Full record

ReviewCancers2026

Gallbladder Cancer: Epidemiology and Prevention.

Spyridon Peppas, Gabriel Amorim Moreira Alves, Gisella Figlioli, Andreas G Tsantes, Rozeta Sokou, Georgios K Nikolopoulos, Fares Ayoub, Stefanos Bonovas, Daniele Piovani

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Spyridon PeppasDepartment of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0002-2661-978X
Gabriel Amorim Moreira AlvesDepartment of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy.ORCID 0009-0003-0148-6401
Gisella FiglioliClinical Epidemiology and Research Center (CERC), Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, MI, Italy.ORCID 0000-0002-0740-1363
Andreas G TsantesMicrobiology Department, "Saint Savvas" Oncology Hospital, 11522 Athens, Greece.ORCID 0000-0002-3695-0759
Rozeta SokouNeonatal Department, National and Kapodistrian University of Athens, Aretaieio Hospital, 11528 Athens, Greece.ORCID 0000-0002-9972-8901
Georgios K NikolopoulosLaboratory of Medical Statistics, Epidemiology and Public Health, Medical School, University of Cyprus, Nicosia 1678, Cyprus.ORCID 0000-0002-3307-0246
Fares AyoubDepartment of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, USA.
Stefanos BonovasClinical Epidemiology and Research Center (CERC), Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, MI, Italy.ORCID 0000-0001-6102-6579
Daniele PiovaniClinical Epidemiology and Research Center (CERC), Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, MI, Italy.ORCID 0000-0002-1414-6639

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is an uncommon but highly lethal malignancy, characterized by striking geographic clustering, late diagnosis, and a prevention profile that differs from other gastrointestinal malignancies. This narrative review synthesizes epidemiologic, mechanistic, clinical, and public-health evidence on GBC determinants with a prevention-oriented lens. Rather than merely cataloguing risk factors, we propose a pragmatic framework that combines epidemiologic credibility, population-attributable burden, baseline risk, biologic plausibility, feasibility, and the benefit-risk balance of possible interventions. The strongest opportunities for prevention arise from risk-stratified management of gallbladder disease and congenital biliary abnormalities, reduction of excess and dysfunctional adiposity, promotion of physical activity, control of chronic Salmonella carriage in endemic settings, and mitigation of selected food- and water-borne toxic exposures. Several other determinants, including diet, alcohol consumption, smoking, reproductive factors, and socioeconomic disadvantage, may inform risk stratification or broader cancer-prevention policy, but currently offer less specific actionability. Effective prevention will require matching interventions to context: population-wide metabolic and lifestyle prevention, targeted clinical management of high-risk gallbladder conditions, and endemic-area strategies addressing infection, environmental exposure, and access to surgery. GBC prevention is therefore possible through carefully evaluated risk-adapted strategies.

Indexed as

aflatoxingallstonesGBCobesityphysical activitypreventionrisk stratificationSalmonella Typhi

Identifiers

PMID42882845
PMCPMC13664541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.